Fig. 2: Pathologic response results.
Non-pCR indicates patients who received additional neoadjuvant chemotherapy following paclitaxel/trastuzumab/pertuzumab. HR hormone receptor, pCR pathologic complete response, RCB residual cancer burden.
Fig. 2: Pathologic response results. | npj Breast Cancer
